Moolenaar Calls to Restrict American Investment in China’s Biotechnology Companies

Chairman John Moolenaar of the Select Committee on China urged Treasury Secretary Scott Bessent to add biotechnology to the prohibited technologies list under the COINS Act of 2025. The request follows increased American investment and intellectual property transfers to China’s biotechnology sector, including Bristol Myers Squibb’s $15 billion deal with Hengrui Pharma.